CARLSBAD, Calif., Dec. 14 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced that its Board of Directors has promoted B. Lynne Parshall, J.D. to Chief Operating Officer, effective immediately. Ms. Parshall retains her position as Chief Financial Officer, and is a Director of the Company.
"This promotion is well-deserved, and appropriately reflects the scope of Lynne's responsibilities at Isis," commented Stanley Crooke, M.D., Ph.D., Isis' President and CEO. "Lynne has been an integral part of Isis' management team for many years, and has been performing COO functions now for quite some time. This promotion recognizes her outstanding contributions and the nature of her current role with the Company."
Ms. Parshall joined Isis in November 1991, and she has served as
Director since 2000, Executive Vice President since 1995, Chief Financial
Officer since 1994 and Secretary since 1991. Ms. Parshall is currently
responsible for overseeing the operations of finance, legal, patents,
manufacturing and business development and is also very involved in the
Company's corporate communications activities. Previously, Ms. Parshall was
a Partner with the firm of Cooley Godward LLP, now Cooley Godward Kronish
LLP, where she represented several health care companies in a general
practice specializing in corporate partnering and other technology-based
transactions. Ms. Parshall received her J.D. at Stanford Law School,
Stanford, California and her B.A. from Harvard University, Cambridge,
Massachusetts. Ms. Parshall is on the board of CardioDynamics International
Corporation and is a Trustee of The Bishop School in La Jolla. Ms. Parshall
is also a member of the Licensing Executives Society and a member of the
|SOURCE Isis Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved